Summary
Industry
Insights
Nouscom, based in Basel, has strong potential in the biotech space with its innovative viral vector-based vaccines for cancer treatment. This technology sets it apart from traditional methods like chemotherapy and radiation, which often have significant side effects and varied effectiveness. The company's direct-to-consumer model allows it to directly address patient needs, fostering closer relationships and potentially quicker adoption of its treatments. Backed by a robust roster of investors, including well-known venture capital firms, Nouscom has the financial support to advance its research and bring its solutions to market. Its focus on viral vectors for cancer vaccines differentiates it in a competitive landscape that relies heavily on older treatment methods.
Investors
Andera Partners Series C
Indaco Venture Partners Series C
M Ventures Series C
M Ventures Series C
Bpifrance Series C
EQT Life Sciences Series C
Angelini Ventures Series C
Versant Ventures Series A
5AM Ventures Series B
Abingworth Series B